Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genta has announced that the FDA is still considering the company's proposal for a confirmatory trial of Genasense Injection in patients with chronic lymphocytic leukemia. The company is waiting for the FDA advice before initiating the trial.
Subscribe to our email newsletter
Genta submitted the trial design to the FDA in December 2005 and then revised its proposal in July 2006 in order to address issues identified by the FDA. However, the company said that it is still waiting for the FDA’s comments on the revised proposal.
“We remain committed to bringing this important product to patients as quickly as possible, while we continue to explore the breadth of its clinical potential,” said Dr Raymond Warrell, chairman and chief executive officer of Genta.
Genta also recently announced its financial results for the second quarter of 2006. The company reported a net loss of $14.6 million compared to net income of $1.9 million for the second quarter of 2005.
The decline in revenue was largely due to the termination of the collaborative agreement to commercialize Genasense that had been in place between Genta and Sanofi-Aventis.